Orion is known for its commercial presence in the European respiratory business space. Our device technology platform has enabled, for instance, the development of a portfolio of inhaled drug products.
However, achieving this position is attributable not only to our technological expertise but also to the value-adding collaborations with our many business partners. Successful partnership management and collaborations throughout the value chain are priorities for us.
While we maximise the value of our respiratory assets together with our partners, we also look to expand our business through in-licensing and the acquisition of marketed, ready-to-market or late-stage assets that would be synergistic to our European respiratory portfolio.
Our focus indications are asthma and chronic obstructive pulmonary disease (COPD), but we are also interested in other indications such as allergy.
We firmly believe that successful companies distinguish themselves not only through superior products or services, but also by the quality of their collaborative ventures. We have decades of experience in partnering with companies of different scale from all over the world, and we are continuously exploring fresh leads for products and alliances to create new value.
We are eager to get to know new potential licensing partners for in-licensing and out-licensing as well as partners and vendors interested in developing technology, products, and production processes with us.
We are also looking for partners who would be interested in placing their molecules in Orion's Dry Powder Inhaler platform.
Our work is always global. Outside Europe, we mostly work with our partners through Partner Sales.
Menarini, a leading Italian pharmaceutical group, has been our co-marketing partner for one Easyhaler® product in selected European countries since 2016.
Since 2016 a British multinational pharmaceutical company Hikma has been our partner for selected Easyhaler® products in the Middle East and North Africa region.
